1.Serum-pharmacological Study of Compound Banmao Capsule on Proliferation of SMMC-7721in Human Hepatocellular Carcinoma Cells
Jun YANG ; Min DING ; Yongyan CAO
China Pharmacy 1991;0(04):-
OBJECTIVE:To investigate the serumpharmacological effects of Compound Banmao Capsule(FBC)on prolif?eration of SMMC-7721cells in human hepatocellular carcinoma.METHODS:The effects of FBC were investigated in vitro using serum pharmacological approach.Different doses(clinic equivalent dosage,duplation and triplicity)of FBC suspension were irrigated into the rabbit stomachs.The inhibitory effects of FBC serum on SMMC-7721cells was observed by MTT assay.The inhibitory effects at different collecting hours in the clinical equivalent group were also observed.RESULTS:All of the drug serums in the three groups could inhibit the proliferation of SMMC-7721cells(P
2.Serological Investigation of STIs in 138 Men Who Have Sex with Men
Jinping ZHANG ; Ningxiao CAO ; Juan JIANG ; Yongyan YOU ; Zhong SA
Chinese Journal of Dermatology 2003;0(09):-
Objective To investigate serologic screening for sexually transmitted infections (STI) in men who have sex with men (MSM) and provide evidence for intervention in the population. Methods A questionnaire investigation was conducted in MSM. Serologic specimens were taken to detect antibodies to HIV, syphilis, herpes simplex virus (HSV)-2, hepatitis C virus, and hepatitis E virus, as well as HBsAg. Results A total of 138 MSM were screened. HIV antibody was negative in all of them. TPPA was reactive in 23 (16.7%) men, among which RPR was positive in 10 (7.2%). The antibodies to HSV-2-IgG, hepatitis C virus, and hepatitis E virus, and HBsAg were found in 7.8%, 0, 16.1% and 9.7% of the men, respectively. Conclusions STIs are identified in this group of MSM. It is important to provide preventive intervention for this population.
3.Factors affecting the severity of disease symptoms in patients with acute leukemia
Huimin PENG ; Yan YAN ; Zhi WANG ; Qin SI ; Yongyan CAO ; Liqing MEN ; Juan WANG
Journal of Leukemia & Lymphoma 2017;26(7):409-412
Objective To explore the factors related to the severity of disease symptoms in patients with acute leukemia (AL). Methods 198 AL patients with symptoms of disease (anemia, bleeding, infection, fever, etc.) from September 2013 to July 2016, were evaluated by the questionnaires of self-rating anxiety scale (SAS), self-rating depression scale (SDS), eysenck personality questionnaire (EPQA), Toronto alexithymia scale (TAS), family environment scale (FES), self-rating scale of illness conception and health seeking behavior (ICHSB). The results were compared with 198 healthy volunteers. Results The scores of SDS, SAS, factorⅠin FES, factor Ⅲ in FES, factor Ⅳ in FES, nervous and the total scores of EPQA, factor Ⅱ in TAS, factor Ⅱ in ICHSB were significantly higher in AL patients than those in healthy subjects [(41.09 ±6.85) scores vs. (36.74±6.99) scores, t=2.150, P=0.031; (38.64±7.51) scores vs. (31.79±7.57) scores, t= 3.327,P=0.001;(2.38±1.54) scores vs. (5.18±1.33) scores, t=3.319, P=0.001;(3.31±1.82) scores vs. (2.23±1.99) scores, t= 3.325, P= 0.001; (2.41±1.62) scores vs. (5.75±1.51) scores, t= 3.332, P= 0.001; (14.14±5.37) scores vs. (11.01±5.51) scores, t= 5.179, P= 0.000; (42.97±7.10) scores vs. (40.41±6.51) scores, t= 2.930, P=0.004;(22.97±4.57) scores vs. (21.54±4.13) scores, t=2.926, P=0.004; (16.37±3.89) scores vs. (15.92± 3.93) scores, t= 2.104, P= 0.034]. The difference was statistically significant (P< 0.05). The risk factors of AL were SAS (95 %CI= 1.064-1.210, P= 0.001), factor Ⅲ in FES (95 %CI= 1.104-1.694, P= 0.004), age (95 %CI= 1.027-1.094, P= 0.001), factor Ⅱ in TAS (95 %CI= 1.046-1.352, P= 0.005), besides, education level (95 %CI= 0.708-0.866, P= 0.001) acted as the protective role. Conclusions AL patients tend to the psychological problems such as depression, anxiety. Those will show much severer symptoms as a consequence of lacking of family warmth and concern, low expression of emotion, lacking of organization, low economic capacity, tension, and lacking of the ability to distinguish between emotion and physical feelings.
4.Effect of resveratrol on the proliferation of malignant melanoma cell lines in vitro
Dongsheng LI ; Yiqan DUAN ; Weizhen WANG ; Liuqing CHEN ; Chenghui ZHANG ; Yongyan CAO ; Zhongsheng TONG
Chinese Journal of Dermatology 2009;42(12):839-842
Objective To investigate the anticancer activities of resveratrol on malignant melanoma cells in vitro and involved mechanisms. Methods A375 human malignant melanoma cells and B16-F1mouse malignant melanoma cells were cultured and treated with various concentrations of resveratrol for different durations. The cell proliferation, apoptosis and cycle of both B16-F1 and A375 cells were detected with MTT assay, Annexin V-F1TC/propidium iodide (PI) double staining flow cytometry and propidium iodide flow cytometry, respectively. Western blot analysis was performed to measure the expression of Bcl-2 and Bax protein in both cells. Results Resveratroi inhibited the proliferation of A375 and B16-F1 cells in a time- and dose- dependent manner. The apoptosis rate of A375 cells was (16.7±2.1 )%, (17.2±1.7)% and (52.3±4.1 )% after treatment with resveratrol of 25 μmol/L for 24 hours, resveratrol of 100 μmol/L for 12 and 72 hours, respectively;, and resveratrol of 100 μmol/L induced the apoptosis of B16-F1 at a rate of ( 18.4±1.6)%, (39.6±3.3 )% and (56.7±4.5 )% at 12, 24 and 72 hours, respectively. Flow cytometry showed that A375 and B16-F1 cells treated with resveratrol were arrested in the G1 phase of cell cycle, and the blocking effect increased in a dose-dependent manner. The percentage of A375 and B16-F1 cells in G1 phase was (40.51±3.97 )% and (41.34±3.12 )%, respectively, after 24-hour treatment with resveratrol of 25 μmol/L,(55.64±4.95)% and (53.93±5.12)%, respectively with resveratrol of 100μmol/L for the same duration.The expression of Bcl-2 protein was decreased in malignant melanoma cells treated with resveratrol,while that of Bax protein increased. Conclusions Resveratrol can effectively inhibit the proliferation of malignant melanoma cells by regulating the cell cycle and inducing cell apoptosis, which seems to be associated with the regulation of Bcl-2 and Bax expressions.
5.Mistakes in Application of Tuina Therapy for Stroke Rehabilitation
Qingyun ZENG ; Yanming XIE ; Xiaolan CAO ; Yongyan WANG ; Xiaoqin YE ; Min WANG ; Guoqi HUANG
Journal of Acupuncture and Tuina Science 2011;09(1):51-54
Objective:To analyze the mistakes in the application of tuina therapy in the rehabilitation of stroke,in order to elevate the clinical effects in the treatment of stroke by tuina.Methods:The issues are found out by searching and analyzing the relevant articles on tuina treatment of stroke.Results:In the tuina treatment of stroke,mistakes exist in the intervening time of the treatment,in the emphasis of tuina with negligence of rehabilitation,in the assessment of therapeutic effects,in the selection of the manual techniques and acupoints,and in the negligence of health education.Conclusion:In the tuina treatment of stroke,it is advisable to start treatment in the early stages,use the manual techniques in different phases,to cooperate with rehabilitation at the proper time and to emphasize health education,in order to avoid or reduce the occurrence of misuse syndrome,and eliminate the appearance of disuse syndrome,for displaying the unique advantage of tuina therapy fully and promoting the innovation and development of TCM rehabilitative techniques.
6.Clinical types and fungal pathogens of children′s tinea capitis analysis of 542 cases in a tertiary first-class hospital of Wuhan
CHEN Zunyi ; YU Huiyuan ; CHEN Yao ; CAO Yongyan ; DONG Bilin ; ZENG Zhiliang ; YANG jing
China Tropical Medicine 2023;23(8):811-
Abstract: Objective To investigate the clinical types of children's tinea capitis and the distribution of fungal pathogens in Wuhan from 2011 to 2020, and to provide scientific basis for the prevention, diagnosis and treatment of children's tinea capitis. Methods Laboratory data of children with tinea capitis in outpatient and inpatient department of dermatology in Wuhan No.1 Hospital from January 2011 to December 2020 were collected. A total of 542 cases of pediatric tinea capitis were included, with 239 male cases and 303 female cases. Microscopic examination of fungi and culture identification were performed on the affected skin lesions of the children. Chi-square test was used to analyze the differences in pathogen spectrum of children with different age groups and clinical type. Results Among the pediatric tinea capitis patients, the age group with the highest prevalence was preschool children(3 to <7 years old), accounting for 48.52%(263/542). The top three pathogenic fungi were Trichophytes violaceum(49.26%, 267/542), Microsporum canis(31.55%, 171/542) and Trichophyton mentagrophytes (9.96%, 54/542). Trichophyton violaceum was the main pathogen in all ages, followed by Microsporum canis. The infection rate of Microsporum canis in children over 7 years old was lower than that in children under 7 years old, and the infection rate of Trichophyton rubrum in infants was higher than that in other ages. The distribution of Trichophytes violaceum, Trichophyton mentagrophytes, Nannizzia gypseum and Microsporum ferrugineum was uniform in all age groups. Trichophytes violaceum and Trichophyton tousurans mainly caused black-dot ringworm, Microsporum canis mainly caused tinea alba, Trichophyton mentagrophytes,Nannizzia gypseum and Trichophytonrubrum mainly caused kerion. Except for Microsporum ferrugineum, the composition ratios of other fungi species showed statistically significant differences among different clinical types of tinea capitis(P<0.05). Conclusions Preschool children are the most commonly affected age group by pediatric tinea capitis, and black-dot ringworm caused by Trichophytes violaceum is the main clinical type. Analysis of the high-riskage group, pathogenic fungi and clinical types of tinea capitis in children can enhance the understanding of its epidemiological characteristics, which is helpful for early diagnosis and targeted standardized treatment of pediatric tinea capitis.
7.Post-marketing re-evaluation of Kudiezi injection study on early treatment in patients with ischemic stroke.
Xiaoqin YE ; Xu WEI ; Yanming XIE ; Yihuai ZOU ; Xingquan ZHAO ; Jianhua HAN ; Xinzhi WANG ; Yunzhi MA ; Qi BI ; Qingfan XIE ; Jianjun ZHAO ; Xiaolan CAO ; Hongxia CHEN ; Shizhong WANG ; Rongmei YAN ; Zucheng HAN ; Danhui YI ; Yongyan WANG
China Journal of Chinese Materia Medica 2011;36(20):2793-2795
OBJECTIVETo study the effect and safety of Kudiezi injection on patients with acute ischemic stroke.
METHODSeven hundreds patients were divided into two groups by central randomization system. The study group, 346 cases, was treated with kudiezi injection plus traditional Chinese medicine (TCM) synthesis rehabilitation project, and the control group, 354 cases, was treated with synthetic rehabilitation project. The patients were treated for 10 to 21 days. Before treatment and at the 7th, 14th and 21th day of treatment, the indexes include NIHSS used for evaluating the neurological deficit degree and the motor function score (Fugl-Meyer) for evaluating motor function were observed. The safety index is defined by adverse observation event and laboratory test. The incidence of adverse events and laboratory tests results were observed before and after treatment at the same time.
RESULTApplication of generalized estimating equation model, we found that as the treatment time, NIHSS score and FMI score of the two groups showed a trend of improvement. And at the 14th days and 21th days of treatment, compared to the control group the treatment group showed significant statistical difference on the impact of NIHSS and FMI (P<0.05). No serious adverse events were observed.
CONCLUSIONKudiezi injection plus TCM rehabilitation project of ischemic stroke showed some superiority to western medicine rehabilitation program on improving the neurological deficit and motor function. Kudiezi injection is safe and effective in the treatment of acute ischemic stroke.
Aged ; Brain Ischemia ; drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Female ; Humans ; Injections ; Male ; Medicine, Chinese Traditional ; adverse effects ; Middle Aged ; Product Surveillance, Postmarketing ; Stroke ; drug therapy
8.Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke.
Xu WEI ; Xiaoqin YE ; Yanming XIE ; Yihuai ZOU ; Xingquan ZHAO ; Jianhua HAN ; Xinzhi WANG ; Yunzhi MA ; Qi BI ; Qingfan XIE ; Jianjun ZHAO ; Xiaolan CAO ; Hongxia CHEN ; Shizhong WANG ; Rongmei YAN ; Zucheng HAN ; Danhui YI ; Yongyan WANG
China Journal of Chinese Materia Medica 2011;36(20):2789-2792
OBJECTIVETo verify the efficacy and safety of post-marketed fleabane injection combined with Dengzhan Shengmai capsules in the treatment of ischemic stroke (IS).
METHODA multicentre, prospective, practical, randomized controlled study was carried out to compare the efficacy and safety of Dengzhan group (n = 343) and western medicine group (n = 335), appling "clinical study central stochastic system". The treatment of Dengzhan group is using fleabane injection in acute stage and Dengzhan Shengmai capsules in convalescence. The primary indexes of effect evaluation are the important outcome events in 360 days' follow-up, including mortality, recurrence, disability and quality of life to reflect the effect of clinical study. The indexes of safety evaluation involve laboratory examination results and incidence of adverse events.
RESULTAfter 360 days' follow-up, 4 people died of IS in Dengzhan group, and the mortality rate of which is 1.17%, while 16 died in Western medicine group (WM group), and the mortality rate is 4.78%, suggesting that the mortality rate of Dengzhan group is significantly lower than WM group (P<0.05). Eleven cases recurred in Dengzhan group, and the recurrence rate of which is 3.21%, while 12 recurred in WM group, and the recurrence rate is 3.59%, indicating that the recurrence rate of Dengzhan group is slightly lower than WM group. The disability rate of Dengzhan group is 39.53%, among which the rate of severely disabled cases are 1.49%, while the disability rate of WM group is 40.13%, among which the rate of severely disabled cases are 3.13%, suggesting that the disability rate of Dengzhan group is lower and the severity of disability is also lighter than WM group. In the field of quality of life, the activity ability and the upper limb function store of stroke patients in Dengzhan group improved far much better than WM group (P<0.05). Analysis of safety suggested that, adverse events occurred in 11 cases in Dengzhan group, among which 4 cases is related with the drug treatment, the incidence of adverse events of which is 1.17%, and the main manifestations involve fever and chilling, rash, nausea, dizziness, palpitation, etc. which were all appeared after the treatment of fleabane injection, and disappeared 1 to 2 days after drug withdrawal. 13 cases occurred abnormal liver function and 2 cases abnormal kidney function in Dengzhan group. According to the judgment of clinical physicians, 3 case of ALT abnormality is possibly related to the treatment, the others are all unrelated with the treatment.
CONCLUSIONFleabane injection and Dengzhan Shengmai capsules are all safe and effective TCM in the treatment of ischemic stroke.
Adult ; Aged ; Brain Ischemia ; drug therapy ; Capsules ; Drug-Related Side Effects and Adverse Reactions ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Erigeron ; adverse effects ; Female ; Humans ; Injections ; Male ; Middle Aged ; Product Surveillance, Postmarketing ; Prospective Studies ; Stroke ; drug therapy
9.Consensus for the management of severe acute respiratory syndrome.
Nanshang ZHONG ; Yanqing DING ; Yuanli MAO ; Qian WANG ; Guangfa WANG ; Dewen WANG ; Yulong CONG ; Qun LI ; Youning LIU ; Li RUAN ; Baoyuan CHEN ; Xiangke DU ; Yonghong YANG ; Zheng ZHANG ; Xuezhe ZHANG ; Jiangtao LIN ; Jie ZHENG ; Qingyu ZHU ; Daxin NI ; Xiuming XI ; Guang ZENG ; Daqing MA ; Chen WANG ; Wei WANG ; Beining WANG ; Jianwei WANG ; Dawei LIU ; Xingwang LI ; Xiaoqing LIU ; Jie CHEN ; Rongchang CHEN ; Fuyuan MIN ; Peiying YANG ; Yuanchun ZHANG ; Huiming LUO ; Zhenwei LANG ; Yonghua HU ; Anping NI ; Wuchun CAO ; Jie LEI ; Shuchen WANG ; Yuguang WANG ; Xioalin TONG ; Weisheng LIU ; Min ZHU ; Yunling ZHANG ; Zhongde ZHANG ; Xiaomei ZHANG ; Xuihui LI ; Wei CHEN ; Xuihua XHEN ; Lin LIN ; Yunjian LUO ; Jiaxi ZHONG ; Weilang WENG ; Shengquan PENG ; Zhiheng PAN ; Yongyan WANG ; Rongbing WANG ; Junling ZUO ; Baoyan LIU ; Ning ZHANG ; Junping ZHANG ; Binghou ZHANG ; Zengying ZHANG ; Weidong WANG ; Lixin CHEN ; Pingan ZHOU ; Yi LUO ; Liangduo JIANG ; Enxiang CHAO ; Liping GUO ; Xuechun TAN ; Junhui PAN ; null ; null
Chinese Medical Journal 2003;116(11):1603-1635